Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtox files drug screening test with FDA :

This article was originally published in Clinica

Executive Summary

Medtox Diagnostics, a subsidiary of Medtox Scientific, has submitted its PROFILE-ER drugs-of-abuse test to the US FDA for 510(k) marketing clearance. The product simultaneously detects nine of the most commonly used drugs-of-abuse - cocaine, amphetamines, cannabinoids, opiates, phencyclidine, benzodiazapine, barbiturate, tricyclic antidepressants and methadone. The test involves a one-step process and produces qualitative results in seven minutes, said St Paul, Minnesota-based Medtox. It will be targeted at hospital laboratories, emergency rooms and the urgent care market, allowing the end-user to perform an on-site screen for the drugs.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT076912

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel